BACK vs. NVOS, AIH, TMDIF, GTBP, LIPO, SSY, CPHI, VERO, THAR, and DRUG
Should you be buying IMAC stock or one of its competitors? The main competitors of IMAC include Novo Integrated Sciences (NVOS), Aesthetic Medical International Holdings Group (AIH), Titan Medical (TMDIF), GT Biopharma (GTBP), Lipella Pharmaceuticals (LIPO), SunLink Health Systems (SSY), China Pharma (CPHI), Venus Concept (VERO), Tharimmune (THAR), and Bright Minds Biosciences (DRUG). These companies are all part of the "medical" sector.
Novo Integrated Sciences (NASDAQ:NVOS) and IMAC (NASDAQ:BACK) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, media sentiment, earnings, dividends, community ranking, profitability, valuation and risk.
IMAC has higher revenue and earnings than Novo Integrated Sciences.
5.7% of Novo Integrated Sciences shares are owned by institutional investors. Comparatively, 5.8% of IMAC shares are owned by institutional investors. 10.9% of Novo Integrated Sciences shares are owned by insiders. Comparatively, 10.0% of IMAC shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Novo Integrated Sciences has a net margin of -88.48% compared to Novo Integrated Sciences' net margin of -176.22%. IMAC's return on equity of -50.54% beat Novo Integrated Sciences' return on equity.
In the previous week, IMAC had 46 more articles in the media than Novo Integrated Sciences. MarketBeat recorded 48 mentions for IMAC and 2 mentions for Novo Integrated Sciences. IMAC's average media sentiment score of 0.30 beat Novo Integrated Sciences' score of 0.19 indicating that Novo Integrated Sciences is being referred to more favorably in the media.
Novo Integrated Sciences and IMAC both received 0 outperform votes by MarketBeat users.
Novo Integrated Sciences has a beta of -1.91, indicating that its share price is 291% less volatile than the S&P 500. Comparatively, IMAC has a beta of 0.19, indicating that its share price is 81% less volatile than the S&P 500.
Summary
Novo Integrated Sciences beats IMAC on 6 of the 11 factors compared between the two stocks.
Get IMAC News Delivered to You Automatically
Sign up to receive the latest news and ratings for BACK and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding BACK and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
